Literature DB >> 8769507

Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis.

J W Becker1, W Burke, G McDonald, P A Greenberger, W R Henderson, M L Aitken.   

Abstract

BACKGROUND: Underestimation of allergic bronchopulmonary aspergillosis (ABPA) prevalence in the cystic fibrosis (CF) population is suspected due to nonuniform diagnostic criteria, nonspecific signs and symptoms, assessment during asymptomatic intervals, and physician nonaggressiveness in making the diagnosis.
OBJECTIVE: To define the prevalence of ABPA in adult patients with CF, as the increased duration of bronchiectasis may increase the probability of Aspergillus fumigatus (Af) colonization. We also sought to determine whether atopy increases the prevalence of ABPA in adults with CF.
METHODS: We examined a cross-sectional population of adult patients with CF at the University of Washington for 1 year.
RESULTS: Information was collected on 53 of 65 (82%) patients. Fifteen of 51 (29%) had an immediate skin test reaction to Af, and 30 of 51 (59%) had at least one positive skin test. Increased total serum IgE (>450 IU/mL) was present in 0 of 53; increased IgE-Af and IgG-Af were found in 12 of 53 (23%) and 9 of 53 (17%), respectively; 24 of 53 (45%) had Af-precipitins. Peripheral blood eosinophilia was present in one patient. Eight of 49 (16%) patients' sputum cultures grew Af. ABPA-CB (ABPA-central bronchiectasis) was present in one patient and ABPA-S (ABPA-seropositive) in no patients. Atopy was present in 20 of 51 (39%).
CONCLUSION: There was a low prevalence of ABPA in the adult CF population despite frequent immunologic responses to Af. The prevalence of ABPA was too small to determine an association with atopy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769507     DOI: 10.1378/chest.109.6.1536

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  20 in total

1.  Sputum itraconazole concentrations in cystic fibrosis patients.

Authors:  I Sermet-Gaudelus; A Lesne-Hulin; G Lenoir; E Singlas; P Berche; C Hennequin
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses.

Authors:  Christian Mueller; Sofia A Braag; Allison Keeler; Craig Hodges; Mitchell Drumm; Terence R Flotte
Journal:  Am J Respir Cell Mol Biol       Date:  2010-08-19       Impact factor: 6.914

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 4.  Asthma in Cystic Fibrosis: Definitions and Implications of This Overlap Syndrome.

Authors:  Chad R Marion; Manuel Izquierdo; Holly C Hanes; Christopher Barrios
Journal:  Curr Allergy Asthma Rep       Date:  2021-02-09       Impact factor: 4.806

5.  Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis.

Authors:  Nicole Ritz; Roland A Ammann; Carmen Casaulta Aebischer; Franziska Schoeni-Affolter; Martin H Schoeni
Journal:  Eur J Pediatr       Date:  2005-05-31       Impact factor: 3.183

Review 6.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

7.  Allergic bronchopulmonary aspergillosis in Italian cystic fibrosis patients: prevalence and percentage of positive tests in the employed diagnostic criteria.

Authors:  G Taccetti; E Procopio; L Marianelli; S Campana
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

8.  Evolution of the Immune Response to Chronic Airway Colonization with Aspergillus fumigatus Hyphae.

Authors:  Mirjam Urb; Brendan D Snarr; Gabriella Wojewodka; Mélanie Lehoux; Mark J Lee; Benjamin Ralph; Maziar Divangahi; Irah L King; Toby K McGovern; James G Martin; Richard Fraser; Danuta Radzioch; Donald C Sheppard
Journal:  Infect Immun       Date:  2015-06-29       Impact factor: 3.441

Review 9.  Allergic bronchopulmonary aspergillosis.

Authors:  Richard B Moss
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

10.  Lung surfactant proteins A and D can inhibit specific IgE binding to the allergens of Aspergillus fumigatus and block allergen-induced histamine release from human basophils.

Authors:  T Madan; U Kishore; A Shah; P Eggleton; P Strong; J Y Wang; S S Aggrawal; P U Sarma; K B Reid
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.